Compare Biogen Inc (BIIB) vs Home Depot Inc (HD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Home Depot Inc — how do they compare? Biogen Inc trades at $202.7 (market cap $30.13B), while Home Depot Inc trades at $353.13 (market cap $353.46B). The key difference: Home Depot Inc is far larger — about 11.7× Biogen Inc's market cap, and Home Depot Inc pays a 2.63% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | HD | |
|---|---|---|
Market Cap | $30.13B | $353.46B |
Sector | Health | Consumer Cyclical |
52-Week High | $216.63 | $423.42 |
52-Week Low | $128.93 | $297.51 |
Enterprise Value | $37.20B | $415.01B |
Dividend Yield | — | 2.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Home Depot (HD) trades at $350.78, down 1.36% on the day, with a bullish technical outlook supported by moving averages and strong institutional support. The company reported $159.51B in revenue for 2025 with solid profitability metrics including 8.41% net margin and 128.38% ROE. Recent earnings show mixed results with Q2 2026 expectations at $4.73 EPS. Analyst consensus remains positive with 59% buy ratings and a $371.25 price target, representing 5.8% upside potential.
The stock presents a compelling long-term opportunity given strong fundamentals and analyst optimism, though near-term headwinds include weakening big-ticket demand and margin pressure from investments. Housing market sensitivity and competitive pressures remain key risks, but Pro business growth and digital initiatives provide resilience. Current valuation at 24.91 P/E appears reasonable for the quality franchise.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Home Depot Inc
Home Depot is the world's largest home improvement specialty retailer, operating more than 2,300 warehouse-format stores offering more than 30,000 products in store and 1 million products online in the United States, Canada, and Mexico. Its stores offer numerous building materials, home improvement products, lawn and garden products, and decor products and provide various services, including home improvement installation services and tool and equipment rentals. The acquisition of distributor Interline Brands in 2015 allowed Home Depot to enter the maintenance, repair, and operations business, which has been expanded through the tie-up with HD Supply (2020). The addition of the Company Store brought textile exposure to Home Depot's lineup.
Read more on HD →
